12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

SDZ ASM 981: Phase III

In NOVN's two 6-week Phase III studies in 403 pediatric patients with mild to moderate atopic dermatitis, 60 percent of SDZ ASM 981-treated patients improved, with 58 percent clear or...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >